Bristol-Myers Squibb stock (US1078421011): ASCO 2026 multiple myeloma data and new China R&D deal in focus

Bristol-Myers Squibb shares on the NYSE traded higher on 05/30/2026 as investors digested positive Phase 3 mezigdomide data in relapsed or refractory multiple myeloma presented at ASCO 2026 and a multibillion-dollar early-stage oncology collaboration with China’s Hengrui, underscoring the US group’s late-stage pipeline and external innovation strategy.

Bristol-Myers Squibb shares on the New York Stock Exchange were in focus on 05/30/2026 after the US pharmaceutical group highlighted positive Phase 3 data for its CELMoD agent mezigdomide in relapsed or refractory multiple myeloma at the ASCO 2026 meeting, alongside a large early-stage R&D collaboration with China-based Hengrui that could be worth up to USD 15.2 billion in total milestones, signaling continued pipeline and partnership momentum for one of the largest US drug makers.

According to a company press release dated 05/29/2026, the Phase 3 SUCCESSOR-2 trial showed that adding mezigdomide to a standard-of-care backbone reduced the risk of disease progression or death by more than 50 percent versus standard therapy alone in heavily pretreated relapsed or refractory multiple myeloma, with median progression-free survival of 18 months compared with 8.3 months in the control arm, data that were selected for a late-breaking presentation at ASCO 2026.

The stock traded at USD 42.30 on 05/30/2026 on the NYSE under the ticker BMY, compared with a 52-week low near USD 39 earlier in the year, according to exchange data, while in Germany the shares were quoted around EUR 39.50 on Tradegate, illustrating that the US-based big pharma name remains actively traded across both its home and secondary markets as investors digest the latest clinical and strategic updates.

The ASCO presentation and the updated mezigdomide dataset are closely watched by US investors because Bristol-Myers Squibb is seeking to build successors to its Revlimid franchise as generic erosion continues, and the improved progression-free survival and response rates reported in SUCCESSOR-2 could help support potential regulatory submissions in the United States and other key markets if the overall benefit-risk profile is confirmed across subgroups.

In parallel, sector specialist publication BioWorld reported on 05/30/2026 that Bristol-Myers Squibb and Jiangsu Hengrui Pharmaceuticals agreed a discovery and development pact covering up to 13 early-stage programs in oncology and immunology, with headline deal value of up to USD 15.2 billion including upfront, development, regulatory and commercial milestone payments, expanding the US company’s access to Chinese innovation while adding to its existing external collaboration portfolio.

While detailed near-term financial terms of the Hengrui deal were not fully disclosed, the structure described by BioWorld on 05/30/2026 suggests a relatively modest upfront outlay compared with the potential long-term milestones, reflecting the early-stage nature of the assets and underscoring Bristol-Myers Squibb’s strategy of using business development to supplement its internal R&D engine in core therapeutic areas like oncology and immunology.

The combination of late-stage clinical news from the United States and an expansive China-linked research collaboration gives US- and Europe-based shareholders multiple data points to assess how Bristol-Myers Squibb is positioning its pipeline for the second half of the decade, at a time when the broader S&P 500 healthcare sector is also reacting to evolving drug pricing rules and competitive dynamics.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bristol-Myers Squibb
• Sector/industry: Biopharmaceuticals, oncology and immunology
• Headquarters/country: New York, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oncology, hematology, cardiovascular and immunology therapies including Revlimid and newer pipeline assets
• Home exchange/listing venue: New York Stock Exchange (BMY)
• Trading currency: USD

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb focuses on discovering, developing and commercializing specialty medicines in areas such as oncology, hematology, immunology and cardiovascular disease, with sales concentrated in branded therapies and new pipeline candidates that aim to replace maturing products.

Insider activity and ownership structure

Recent disclosures filed with the US Securities and Exchange Commission indicate that institutional investors continue to represent a large share of Bristol-Myers Squibb’s shareholder base, with major asset managers and pension funds among the top holders, while company insiders, including executives and directors, own only a small percentage of the outstanding float, a typical pattern for large-cap US pharmaceutical companies.

Within the last few months, routine Form 4 filings have captured periodic stock grants and sales by members of senior management in connection with long-term incentive plans, but there have been no large, concentrated insider buying waves reported in public filings that would materially alter the ownership structure, meaning that free float remains broadly dispersed among US and international institutional investors and retail shareholders.

Conclusion

The latest ASCO 2026 data from the Phase 3 SUCCESSOR-2 trial, showing a greater than 50 percent reduction in the risk of disease progression or death and an 18-month median progression-free survival in the mezigdomide arm, provide a new datapoint for how Bristol-Myers Squibb is addressing the treatment needs of patients with relapsed or refractory multiple myeloma while seeking to offset Revlimid erosion.

At the same time, the up-to-USD-15.2-billion collaboration with Hengrui described on 05/30/2026 highlights the US group’s willingness to tap external innovation ecosystems, particularly in China, to broaden its early-stage oncology and immunology pipeline, which could become increasingly relevant for investors tracking the company’s long-term growth and competitive dynamics.

Against this backdrop, trading in New York and on German venues will likely continue to reflect how market participants weigh the strength of the late-stage hematology pipeline and the potential of new partnerships against ongoing pricing, competition and patent challenges across Bristol-Myers Squibb’s broader portfolio.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.